Očovská Zuzana, Maříková Martina, Vlček Jiří
Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
Department of Clinical Pharmacy, Hospital Pharmacy, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
Front Pharmacol. 2023 Feb 2;14:1088900. doi: 10.3389/fphar.2023.1088900. eCollection 2023.
An international consensus list of potentially clinically significant drug-drug interactions (DDIs) in older people has been recently validated. Our objective was to describe the prevalence and characteristics of drug combinations potentially causing clinically significant DDIs identified in the medication history of older patients admitted to the hospital and the prevalence and characteristics of manifest DDIs-DDIs involved in adverse drug events present at hospital admission, DDIs that contributed to ADE-related hospital admissions, and DDIs involved in drug-related laboratory deviations. The data were obtained from our previous study that examined the drug-relatedness of hospital admissions to University Hospital Hradec Králové the department of emergency medicine in the Czech Republic. Patients ≥ 65 years old were included. Drug combinations potentially causing clinically significant DDIs were identified using the international consensus list of potentially clinically significant DDIs in older people. Of the 812 older patients admitted to the hospital, 46% were exposed to drug combinations potentially causing clinically significant DDIs. A combination of medications that affect potassium concentrations accounted for 47% of all drug combinations potentially causing clinically significant DDIs. In 27 cases, potentially clinically significant DDIs were associated with drug-related hospital admissions. In 4 cases, potentially clinically significant DDIs were associated with ADEs that were present at admissions. In 4 cases, the potentially clinically significant DDIs were associated with laboratory deviations. Manifest DDIs that contributed to drug-related hospital admissions most frequently involved antithrombotic agents and central nervous system depressants. The results confirm the findings from the European OPERAM trial, which found that drug combinations potentially causing clinically significant DDIs are very common in older patients. Manifest DDIs were present in 4.3% of older patients admitted to the hospital. In 3.3%, manifest DDIs contributed to drug-related hospital admissions. The difference in the rates of potential and manifest DDIs suggests that if a computerized decision support system is used for alerting potentially clinically significant DDIs in older patients, it needs to be contextualized (e.g., take concomitant medications, doses of medications, laboratory values, and patients' comorbidities into account).
一份关于老年人潜在临床显著药物相互作用(DDIs)的国际共识清单最近得到了验证。我们的目标是描述在入院老年患者用药史中识别出的可能导致临床显著DDIs的药物组合的患病率和特征,以及明显DDIs的患病率和特征——入院时存在的药物不良事件所涉及的DDIs、导致与药物不良事件相关的住院的DDIs,以及涉及药物相关实验室偏差的DDIs。数据来自我们之前的一项研究,该研究调查了捷克共和国赫拉德茨克拉洛韦大学医院急诊科入院与药物的相关性。纳入了年龄≥65岁的患者。使用老年人潜在临床显著DDIs的国际共识清单识别可能导致临床显著DDIs的药物组合。在812名入院的老年患者中,46%接触过可能导致临床显著DDIs的药物组合。影响钾浓度的药物组合占所有可能导致临床显著DDIs的药物组合的47%。在27例病例中,潜在临床显著DDIs与药物相关的住院有关。在4例病例中,潜在临床显著DDIs与入院时存在的药物不良事件有关。在4例病例中,潜在临床显著DDIs与实验室偏差有关。导致药物相关住院的明显DDIs最常涉及抗血栓药物和中枢神经系统抑制剂。结果证实了欧洲OPERAM试验的结果,该试验发现可能导致临床显著DDIs的药物组合在老年患者中非常常见。4.3%的入院老年患者存在明显DDIs。在3.3%的患者中,明显DDIs导致了与药物相关的住院。潜在DDIs和明显DDIs发生率的差异表明,如果使用计算机化决策支持系统来提醒老年患者潜在的临床显著DDIs,则需要将其置于具体情境中(例如,考虑同时使用的药物、药物剂量、实验室值和患者的合并症)。